Key result
AI model detects structural heart disease from single-lead ECGs with ~0.87 AUROC for reduced LVEF.
Why the study?
Early detection of structural heart disease is constrained by limited echocardiography access. Existing AI ECG screening models often rely on 12-lead inputs, generalize poorly across institutions, or require massive, condition-specific labeled datasets.
Does the AnyECG-Echo framework accurately detect 13 fine-grained structural heart disease subtypes from single-lead ECGs compared to echocardiography reports in internal and external validation cohorts?
Observational (n=25,222)
Yes
Does the AnyECG-Echo framework accurately detect 13 fine-grained structural heart disease subtypes from single-lead ECGs compared to echocardiography reports in internal and external validation cohorts?
This study demonstrates that a report-supervised multimodal contrastive learning framework applied to single-lead ECGs can accurately screen for 13 specific structural heart disease subtypes across geographically distinct cohorts, enabling scalable out-of-hospital screening.
Answers are grounded in this paper and cite their sources.
May support single-lead ECG screening for structural heart disease; leaves open prospective validation before clinical adoption.
Structural heart disease (SHD) is a primary driver of heart failure and cardiovascular mortality, yet early detection remains constrained by the limited accessibility of echocardiography. While single-lead electrocardiogram (ECG) is ubiquitous through wearables, existing AI screening models often depend on 12-lead inputs, generalize poorly across institutions, or require massive, condition-specific labeled datasets. Recent work has demonstrated the feasibility of contrastive pre-training between single-lead ECGs and echocardiography reports within a single health system. Here, we present AnyECG-Echo, a framework that advance this paradigm toward clinical translation through three key developments: (1) evaluation in a geographically independent external cohort (n = 16,621); (2) diagnostic coverage of 13 fine-grained SHD subtypes spanning myocardial, chamber, valvular, and great-vessel pathologies; and (3) dual-axis mechanistic interpretability combining electrophysiology-grounded Shapley attribution with emergent correlations to quantitative measurements. Across validation cohorts totaling n = 25,222, the model demonstrated high AUROC for high-impact subtypes, including reduced left ventricular systolic functon(AUROC 0.866–0.924), global heart enlargement (0.877–0.931), and mitral stenosis (0.836–0.906). Furthermore, we successfully validated the alignment of model outputs with established medical physiological traits, thereby enhancing interpretability. Notably, we discovered that AnyECG-Echo’s outputs function as physiologically grounded digital biomarkers that accurately track objective metrics such as LVEF and myocardial wall thickness. These findings prove that wearable single-lead ECGs can effectively detect fine-grained structural heart disease, offering a practical solution for population-scale screening.
No takes yet. Share an insight, caveat, or question.
Hong et al. (2026) conducted an observational in Structural heart disease (n=25,222). AnyECG-Echo single-lead ECG screening model vs. Physician-authored echocardiography reports was evaluated on Diagnostic discrimination (AUROC) for 13 structural heart disease subtypes, including reduced left ventricular systolic function in the external validation cohort (AUROC 0.866, 95% CI 0.858-0.874). AnyECG-Echo detected 13 structural heart disease subtypes from single-lead ECGs with high accuracy, achieving AUROCs of 0.866–0.924 for reduced LV systolic function and 0.877–0.931 for global heart enlargement.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: